Figure 4
From: Safe electrophysiologic profile of dexmedetomidine in different experimental arrhythmia models
(A,B) Cycle-length dependent action potential durations (APD90) and QT interval under baseline conditions (◆), after infusion of 300 µM erythromycin (■) and after additional treatment with 3 µM dexmedetomidine (▲). (C) Impact of erythromycin (Ery) and dexmedetomidine (Dex) on spatial dispersion of repolarization. (D) Occurrence of early afterdepolarizations (EAD) after administration of erythromycin and after additional treatment with dexmedetomidine. (E) Incidence of torsade de pointes under baseline conditions, with erythromycin and with the combination of erythromycin and dexmedetomidine (# = p < 0.05 compared to baseline conditions; * = p < 0.05 compared to sole erythromycin infusion).
